| Document |
Document Title |
|
WO/2018/080072A2 |
The present invention relates to a novel macrolide-based compound, a method for producing the same, and a pharmaceutical composition, which is for preventing or treating malaria and contains the novel macrolide-based compound as an activ...
|
|
WO/2018/074794A1 |
The present specification relates to a novel quercetin-based compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, the compound being capable of...
|
|
WO/2018/074776A1 |
The present specification relates to a novel compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, the compound being capable of being widely us...
|
|
WO/2018/066916A1 |
The present invention provides a novel Scenedesmus sp. algae, and an extract thereof. This extract of Scenedesmus sp. JD-052, which is a novel Scenedesmus sp. algae, shows a UV protection effect, and thus can be usefully used in the fiel...
|
|
WO/2018/053706A1 |
A composition comprises a compound of formula (I) and at least one cosmetically acceptable carrier. It can be used for preventing or decreasing skin pigmentation and /or lightening skin tone.
|
|
WO/2018/045294A1 |
Processes and intermediates for preparing fluoroketolide compounds are described herein.
|
|
WO/2018/039923A1 |
A preparation method of diosmin, comprising: A) mixing an amide solvent, hesperidin, an alkaline reagent, with iodine, and heating to react to obtain diosmin. Compared with the prior art, the amide solvent used as a reaction solvent has ...
|
|
WO/2018/035410A1 |
The present invention relates to the discovery that size-expanded DNA nucleotides and analogs thereof inhibit Ροlθ DNA synthesis activity.
|
|
WO/2018/021544A1 |
The present invention provides a 6-acyl-2-O-α-D-glycosyl-L-ascorbic acid represented by general formula (3) (in the formula, n denotes an integer of 1 or higher and R denotes a hydrocarbon group) and/or a composition containing this com...
|
|
WO/2018/021542A1 |
Provided are a metal salt of 2-O-α-D-glycosyl-L-ascorbic acid represented by general formula (1) (in the formula, n denotes an integer of 1 or higher), an amorphous powder thereof, and a method for producing same. Also provided is an an...
|
|
WO/2018/010170A1 |
Provided is a novel embodiment of a flavonoid with reduced hygroscopicity and improved storage stability. The flavonoid is applicable for preparing a food, health food, or pharmaceutical product or composition thereof to provide preventi...
|
|
WO/2018/003686A1 |
[Problem] To provide a fluorescent imaging probe with which it is possible to visualize target cells, such as cells expressing β-galactosidase (lacZ expressing cells), at a single cell level in a selective manner by using a red fluoresc...
|
|
WO/2017/221269A1 |
The present invention pertains to the enhanced activity of (+) epicatechin over (-) epicatechin. The present invention is related to novel analogs of (+) epicatechin of the formula (I), which enhances the pharmacokinetics and therefore t...
|
|
WO/2017/219509A1 |
Disclosed are a quinoid chalcone and flavonol conjugate having an anti-tumor activity and an anti-inflammatory activity and a preparation method therefor. Analyses on wave spectrum and mass spectrum data show that a compound (formula I) ...
|
|
WO/2017/210565A1 |
Compounds of formula (I) or formula (II), compositions and methods useful for treating and/or preventing a fungal infections are provided. wherein the substituents are as defined in the appended claims.
|
|
WO/2017/199028A1 |
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...
|
|
WO/2017/194452A1 |
The present invention relates to seco (opened ring) macrolide compounds of formula (I), to the process for preparation thereof, to the use of said seco macrolide compounds as intermediates for preparation of macrolide based macrocycles, ...
|
|
WO/2017/183972A1 |
Provided is a particular form of natamycin that shows improved properties as a fungicide for use in agricultural applications. A preferred natamycin composition comprises a structuring agent and a surfactant, Said natamycin composition f...
|
|
WO/2017/177228A1 |
Provided herein are complexes comprising amphotericin B (AmB) or derivatives and sterols. Also provided herein are methods of treating cystic fibrosis using AmB or complexes comprising AmB or derivatives and sterols.
|
|
WO/2017/173957A1 |
The present invention relates to the use of a compound of formula (I) below in the control of harmful insects in agricultural and forest crops, wherein R is selected from -CH3 or -C2H5, and the compound is tenvermectin A when R is -CH3 a...
|
|
WO/2017/152273A1 |
Methods that may be used for the manufacture of a class of chemical compounds known as terpenoid indole alkaloids, including tabersonine and catharanthine are provided. Compositions useful for the synthesis of terpenoid indole alkaloids,...
|
|
WO/2017/151575A1 |
This invention is based on the discovery that homogeneous catalysts, [Rh(C2H4)2Cl]2 and/or [Rh(COD)2][BF4], can be used to produce spinetoram in higher yields at lower catalyst loadings as compared to previous methodologies. In addition,...
|
|
WO/2017/147624A1 |
Described are arylnaphthalene lactone derivatives. Also disclosed herein are methods of use of the arylnaphthalene lactone derivatives as anticancer agents.
|
|
WO/2017/142002A1 |
Provided is, for example, an A-form crystal, etc., of a compound represented by formula [1], which has physical property (a) and/or physical property (b), and has excellent physical properties in environments in which it is produced or u...
|
|
WO/2017/136399A1 |
The present invention relates to the use of immune regulatory oligonucleotide (IRO) compounds as antagonists of toll-like receptors (TLRs) to inhibit and/or suppress a TLR-mediated immune response induced by endogenous and/or exogenous n...
|
|
WO/2017/124222A1 |
Disclosed are a method and an intermediate for preparing a tulathromycin. The method comprises the following step: in an organic solvent, subjecting a compound represented by formula (II) and an n-propylamine to a ring-opening addition s...
|
|
WO/2017/124969A1 |
Provided are a dicaffeoyl-spermidine cyclic derivative and a use. Biological activity tests show that the dicaffeoyl-spermidine cyclic derivative has anti-senile dementia activity and antioxidant activity, the activity of the derivative ...
|
|
WO/2017/121855A1 |
The present invention relates to compounds of formula (I) These compounds are useful in the treatment of many diseases such as a skin disease, an allergy, an autoimmune disease, a cardiovascular disease, a lung disease, asthma, a bacteri...
|
|
WO/2017/118690A1 |
The present invention relates to an efficient route of synthesis of solithromycin and to a method of its purification which obviates the necessity of chromatographic purifications and improves the quality of the product by efficiently re...
|
|
WO/2017/100171A1 |
Compounds of the Formula (I) and (II) as described herein, or pharmaceutically acceptable salts thereof, are described, along with pharmaceutical compositions comprising such compounds, salts or combinations thereof, and methods for maki...
|
|
WO/2017/085329A1 |
The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention fur...
|
|
WO/2017/080313A1 |
Provided a compound of formula (I): or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the compound is tetrahydropalmatine deriv...
|
|
WO/2017/080520A1 |
A method for extracting avermectin B2 from an avermectin ointment comprises: dissolving an avermectin ointment into a crystallizing solvent, separating crystals out by cooling, and performing vacuum filtrating, thus obtaining an avermect...
|
|
WO/2017/072295A1 |
A first aspect of the invention relates to novel compounds and more precisely to novel bifunctional prodrugs and drugs. An additional aspect of the invention relates to antibody compound conjugates, wherein the compound is a claimed comp...
|
|
WO/2017/069565A1 |
The present invention relates to a method for selectively producing ginsenoside Rd, which is originally present in a trace amount in ginseng, from panaxadiol-based saponins in ginseng and, more specifically, to a method capable of obtain...
|
|
WO/2017/069561A1 |
The present invention relates to a method for selectively producing ginsenoside F2, compound Mc, and compound O, which is originally present in ginseng in trace amounts, from saponins of ginseng and, more specifically, to a method capabl...
|
|
WO/2017/069569A1 |
The present invention relates to a method for selectively producing compound K and compound Y, which are originally present in trace amounts in ginseng, from saponins of ginseng and, more specifically, to a method capable of obtaining de...
|
|
WO/2017/057851A1 |
The present invention relates to a ginsenoside fatty acid ester compound, a method for preparing same, and a cosmetic composition comprising same and, more specifically, to a ginsenoside fatty acid ester compound, modified into a fatty a...
|
|
WO/2017/055502A1 |
The invention relates to an improved process for the preparation of selamectin of formula 5.
|
|
WO/2017/057460A1 |
Provided is a method for producing an organic compound, wherein the organic compound is an industrially useful compound, and a deodorization step, for removing from a reaction solution odorants that are generated in or remaining after a ...
|
|
WO/2017/057852A1 |
The present invention relates to a ginsenoside fatty acid ester compound, a method for preparing same, and a cosmetic composition comprising same and, more specifically, to a ginsenoside fatty acid ester compound, modified into a fatty a...
|
|
WO/2017/057461A1 |
A production method for producing an aldehyde compound or a ketone compound by oxidizing a primary or secondary alcohol compound, wherein the alcohol compound has, in the molecule thereof, a group selected from an amino group, an azide g...
|
|
WO/2017/058953A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing a nucleic acid.
|
|
WO/2017/050032A1 |
A ketolide antibiotics intermediate, a preparation method therefor, and application thereof in preparation of solithromycin. The ketolide antibiotics intermediate has a compound structural general formula as shown as follows, and can be ...
|
|
WO/2017/040769A1 |
Compositions and methods for the production of derivatives of spinosyns are provided. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and/or nematodes and are useful in the agricultural and anim...
|
|
WO/2017/040763A1 |
Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include spinosyn derivatives functionalized on the C5-C6 double bond of th...
|
|
WO/2017/040878A1 |
Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-13,14 double bond to provide an addi...
|
|
WO/2017/040882A1 |
Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include spinosyn derivatives functionalized on the C5-C6 double bond of sp...
|
|
WO/2017/028766A1 |
Disclosed are a method for preparing a taxane derivative of formula 2, and a compound of formula 1 which is used as a raw material or intermediate for preparing the taxane derivative of formula 2.
|
|
WO/2017/013637A1 |
Provided herein are alpha2-selective Na,K-ATPase inhibitors, characterized by having a cyclic moiety attached to a digoxin or digitoxin derivative, as well as uses thereof in lowering intraocular pressure and in treating glaucoma and hea...
|
